AAWH Ascend Wellness Holdings, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1756390 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-10.9%
TTM net income YoY-39.1%
TTM EPS YoY-45.0%
Revenue 3-yr CAGR7.2%
Net income 3-yr CAGR—
Margins
Gross margin33.9%
Operating margin-3.4%
Net margin-23.6%
FCF margin2.4%
EBITDA margin8.2%
Returns
ROE-1,004.3%
ROA-13.1%
ROIC (approx.)-6.1%
Asset turnover0.55x
Leverage & solvency
Liabilities / assets105.1%
Debt / equity—
Current ratio1.92x
Interest coverage-0.33x
Cash quality & payout
Operating cash flow / net income-0.32x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $130.02M | $126.12M | $116.93M | $120.55M | $124.73M | $127.30M | $128.00M | $136.01M |
| Cost of revenue | $76.93M | $80.63M | $72.05M | $75.42M | $81.13M | $85.91M | $88.44M | $89.14M |
| Gross profit | $53.09M | $45.49M | $44.88M | $45.13M | $43.60M | $41.39M | $39.56M | $46.87M |
| SG&A expense | $48.59M | $40.21M | $42.34M | $45.30M | $44.93M | $42.39M | $37.08M | $40.77M |
| Operating income | $4.50M | $5.28M | $2.55M | -$17.17M | -$1.32M | -$1.00M | $2.49M | $6.10M |
| Interest expense | $21.98M | $20.80M | $20.25M | $15.48M | $12.56M | $12.06M | $11.19M | $11.71M |
| Pretax income | -$17.42M | -$15.53M | -$17.59M | -$32.47M | -$13.55M | -$12.58M | -$8.23M | -$6.00M |
| Income tax | $10.53M | -$5.72M | $11.91M | $16.24M | $12.28M | $11.83M | $11.03M | $10.79M |
| Net income | -$27.95M | -$9.81M | -$29.49M | -$48.70M | -$25.82M | -$24.41M | -$19.26M | -$16.79M |
| EBITDA | $15.47M | $15.81M | $20.83M | $3.36M | $8.52M | $8.25M | $20.89M | $23.57M |
| EPS (basic) | -0.14 | -0.05 | -0.15 | — | -0.13 | -0.12 | -0.09 | — |
| EPS (diluted) | -0.14 | -0.05 | -0.15 | — | -0.13 | -0.12 | -0.09 | — |
| Weighted avg. shares (diluted) | 203.23M | 203.01M | 202.45M | — | 202.97M | 203.87M | 205.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $63.62M | $67.00M | $60.92M | $85.68M | $87.27M | $95.27M | $100.03M | $88.25M |
| Receivables | $24.64M | $26.26M | $26.42M | $27.02M | $28.85M | $30.64M | $36.72M | $36.54M |
| Inventory | $82.79M | $82.27M | $87.15M | $84.71M | $82.68M | $82.32M | $85.59M | $89.55M |
| Current assets | $181.19M | $186.87M | $188.96M | $208.95M | $209.21M | $225.65M | $237.38M | $229.38M |
| PP&E, net | $376.01M | $381.56M | $376.60M | $382.40M | $288.90M | $277.90M | $261.78M | $260.46M |
| Goodwill | $71.13M | $65.37M | $58.35M | $58.45M | $57.78M | $54.00M | $51.23M | $49.60M |
| Intangibles | $191.46M | $195.96M | $189.50M | $196.07M | $206.87M | $206.70M | $210.99M | $205.50M |
| Total assets | $879.80M | $888.32M | $872.09M | $907.93M | $900.36M | $903.87M | $916.73M | $900.43M |
| Current liabilities | $116.31M | $112.64M | $88.46M | $109.01M | $96.00M | $100.79M | $147.92M | $144.54M |
| Short-term debt | $29.34M | $25.31M | $9.78M | $10.37M | $25.30M | $26.14M | $81.41M | $72.69M |
| Long-term debt | $294.72M | $293.52M | $292.31M | $291.10M | $343.75M | $323.44M | $251.61M | $214.42M |
| Total debt | $324.06M | $318.82M | $302.09M | $301.47M | $369.05M | $349.58M | $333.02M | $287.11M |
| Total liabilities | $992.21M | $973.41M | $947.86M | $954.55M | $897.78M | $875.71M | $864.03M | $828.63M |
| Shareholders' equity | -$113.23M | -$85.91M | -$76.59M | -$47.44M | $1.75M | $27.33M | $51.88M | $70.98M |
| Net debt | $260.43M | $251.82M | $241.17M | $215.80M | $281.78M | $254.31M | $232.98M | $198.86M |
| Shares outstanding | — | — | 202.82M | 202.22M | 202.61M | 203.31M | 205.23M | 205.03M |
| Cash flow statement | ||||||||
| Operating cash flow | $5.43M | $22.45M | -$19.41M | $16.32M | -$2.00M | $17.80M | $5.94M | $35.17M |
| Capital expenditure | $4.79M | $5.78M | $5.18M | $6.89M | $6.45M | $6.24M | $6.42M | $5.02M |
| Free cash flow | $638,000 | $16.67M | -$24.59M | $9.42M | -$8.45M | $11.56M | -$484,000 | $30.14M |
| Investing cash flow | -$8.56M | -$13.09M | -$4.75M | -$16.76M | -$12.54M | -$8.59M | -$7.85M | -$7.19M |
| Financing cash flow | -$243,000 | -$3.28M | -$592,000 | -$1.15M | $6.54M | -$13.98M | $13.69M | -$5.00M |
| Depreciation & amortization | $10.97M | $10.53M | $18.28M | $20.53M | $9.84M | $9.25M | $18.40M | $17.47M |
| Stock-based compensation | $648,000 | $499,000 | $450,000 | $501,000 | $806,000 | $511,000 | $628,000 | $2.81M |
| Share buybacks | $0 | $0 | $0 | — | $586,000 | $649,000 | $345,000 | — |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.